u/kofi_balogun

Yes. Repeat before you react. Almost every alarming single value I have posted here regressed on the repeat.

Yes — same lab, same fasting state, same rough time of day, or the comparison is doing nothing.

Added ApoB to the panel after a thread here. It told me something the standard lipid panel had been hiding.

What the glucagon arm is doing, as best anyone can say from public data.

Disagree with this specific inference. A 48-week readout does not tell you the shape of the curve after it.

2.5mg is a four-week starting dose, not a maintenance dose.

Not sure about this bit. The GIP arm being real does not tell you that it is what caused your particular week.

Vials and pens carry the same molecule; what differs is fill volume, device tolerance and whether you are doing your own arithmetic. Neither is inherently more accurate.

This. Reference ranges are population intervals, not targets, and conflating them causes a lot of unnecessary alarm here.

Small fix — three receptors, not two. GLP-1, GIP and glucagon, and the third one is the reason this compound gets its own board.

same lab, same conditions, or you are comparing noise

Agreed — and standardising the draw conditions is the cheapest improvement available.

Yes — same lab, same fasting state, same rough time of day, or the comparison is doing nothing.

the glucagon component is why the metabolic story reads differently

Held 7.5 for five months. Everyone kept asking when I was going to 10. The answer was never, because 7.5 was working.

The thing that surprised me was how much of the discussion here is inference rather than measurement.

Push back: quoting the phase 2 headline as an expected outcome is not a fair reading of a small trial with wide intervals.

Agreed, and the trial number is a mean of a very wide distribution — the tails are enormous and nobody posts from the middle.

Weekly dosing again, half-life in the same neighbourhood as sema, so a step change takes about a month to reach steady state. Judging a new step at day five is judging noise.

Yes. I stepped to 12.5 because the calendar said so, not because anything needed fixing, and I regretted it for a fortnight.

What did the repeat show?

The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 39 is not a fair reading.

comparing reta phase 2 to sema phase 3 is comparing different things

Agreed, and the glucagon arm is exactly why the comparison threads do not work.

The phase 2 readout ran to 48 weeks in a few hundred participants with a slow escalation. Both the size and the duration matter when people quote the headline number.

Different laboratories use different assay platforms with different calibration. Comparing across labs adds a systematic offset that is invisible on the report.

the phase 2 numbers were striking and they were also 48 weeks in a small population

honest_syringe33 is right about the escalation being the variable. It explains most of the difficult reports here.

small trial, big effect, wide error bars

Increases in heart rate have been reported across this receptor class. The magnitude and clinical significance are exactly what phase 3 is powered to establish.

Push back: "gentler than sema" is a population statement. Plenty of people on this board have the opposite experience and they are not doing it wrong.

This. The phase 2 result was genuinely large and it was also 48 weeks in a few hundred people.

I would separate the two claims. That the GIP arm exists is uncontroversial; that it explains your fatigue pattern is a guess.

Correction: TRIUMPH is the phase 3 programme.

This is the sentence the rest of the board should read first. Phase 2 is not a label.

The distribution matters more than the mean. In the trial population the interquartile spread was wide enough that two honest people can have completely different runs on the same arm.

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

What did the repeat show?

Which week did the appetite change actually land for you?

Fasting or not, and what time of day?

Glucagon receptor agonism is associated with increased energy expenditure and with hepatic effects. That is a mechanistic story with strong preclinical support and limited phase 2 human data.

Substantial weight loss independently moves lipids, liver enzymes and several other markers. Attributing a change to a compound while losing weight is confounded by design.

ask whether the lab changed its assay between your two draws

Pen or vial? The step sizes available differ and it changes this answer.

not approved anywhere, which is the single most important fact in this board

Are you comparing against phase 3 numbers for something else? They are not comparable.